Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01808157Phase 2Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis

Role: lead

NCT01465282Phase 2Completed

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Role: lead

NCT01243307Phase 1Completed

A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Role: lead

NCT01368315Phase 1Withdrawn

CT 327 in the "Atopy Patch Test" Model

Role: lead

NCT00995969Phase 2Completed

CT 327 in the Treatment of Psoriasis Vulgaris

Role: lead

NCT01243502Phase 1Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

Role: lead

NCT00996008Phase 2Terminated

CT 327 in the Treatment of Atopic Dermatitis

Role: lead

All 7 trials loaded